In conclusion, our study demonstrates that PKC inhibitor treatment is sufficient to trigger inflammasome activation in monocytes from FMF patients, which (i) expands our knowledge on the molecular basis sustaining Pyrin inflammasome deregulation in FMF, (ii) offers a potential functional assay to characterize MEFV variants, and (iii) provides a fast biological test that may discriminate FMF patients from patients suffering from other inflammatory conditions. The gene discussed is PRRT2; the disease is familial Mediterranean fever.